Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Narayana Hrudayalaya jumps 6% after Q4FY26 results, dividend announcement
For the January to March quarter of FY26, Narayana Hrudayalaya delivered record revenue and profit growth, driven by strong operational performance across geographies.
Six pharma stocks that should be on your radar today over various news triggers
It was a busy weekend for pharma stocks as four of them — Divi's Laboratories, Fortis Healthcare, Torrent Pharma and Narayana Hrudayalaya — reported their quarterly results. Meanwhile, Lupin marked its entry into the Chinese market, while Glenmark Pharma's US arm settled an anti-trust litigation. Here's a look at these names in detail:
Narayana Hrudayalaya consolidated net profit rises 13.52% in the March 2026 quarter
Sales rise 75.80% to Rs 2593.81 crore
Trade Spotlight: How should you trade Narayana Hrudayalaya, HDFC Life, Apollo Hospitals, Eternal, Laurus Labs, Max Healthcare, and others on May 12?
Consolidation is likely to continue in the market. Below are some short-term trading ideas to consider.
Buy Narayana Hrudayalaya; target of Rs 2250: Prabhudas Lilladher
Prabhudas Lilladher is bullish on Narayana Hrudayalaya has recommended buy rating on the stock with a target price of Rs 2250 in its research report dated May 27, 2026.
Trade Spotlight: How should you trade Narayana Hrudayalaya, ABB India, Federal Bank, Premier Energies, Ather Energy, and others on June 4?
The market is expected to remain range-bound, with Wednesday's low acting as a support level going forward. Below are some short-term trading ideas to consider.